Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

CVS reportedly makes bid for Aetna

U.S. pharmacy operator CVS Health Corp. made an offer to acquire No. 3 U.S. health insurer Aetna Inc. for more than $200 per share, or over $66 billion, sources said.

Read More »

Endo International units sue FDA over drug compounding policy

Endo International Plc said two units filed a lawsuit accusing the U.S. Food and Drug Administration of ignoring key components of a law passed after a deadly 2012 meningitis outbreak linked to a compounding pharmacy.

Read More »

Outcome Health Announces Partnership with Navicent Health

Outcome Health announced a partnership with Navicent Health. The partnership will bring the Outcome Health platform to Navicent Health Physicians Group, which includes over 100 active physicians and their medical/surgical practices.

Read More »

Despite $9B Setback, Eli Lilly Boldly Moves on With Five New Alzheimer’s Candidates

During a fireside chat at BIO International in San Diego in summer 2017, Daniel Skovronsky – now president of Lilly Research Labs – confirmed Eli Lilly’s commitment to finding an effective therapy for Alzheimer’s disease. Lilly continues to push forward. EP Vantage highlighted and analyzed the company’s five Phase I programs for Alzheimer’s disease. Much like what Skovronsky said about learning from the Phase III solanezumab failure, EP Vantage pointed to some of the hopes the Lilly programs have for blocking the development of amyloid plaques.

Read More »

Disruption, Explained

The theory and practice of overturning marketing conventions.

Read More »

AbbVie Touts Late-Stage Psoriasis Drug Trial Data

AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster Humira or J&J’s Stelara in treating moderate-to-severe chronic plaque psoriasis.

Read More »

Amgen Discontinues Quest for New CETP Heart Drug

In the company’s third-quarter 2017 report, Amgen Inc. announced it scrapped internal development of AMG 899, an oral CETP inhibitor it acquired in the $1.2 billion deal for Netherlands-based Dezima Pharma BV.

Read More »

Billionaire Insys founder charged in U.S. opioid bribe case

The billionaire founder of Insys Therapeutics Inc. was arrested on U.S. charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

Read More »

Trump declares opioid epidemic a public health emergency; crisis could spread to Europe, experts say

As U.S. President Donald Trump declared the opioid crisis a public health emergency, Europe should heed the threat from opioids responsible for America’s deadliest drug epidemic in decades as both regions have seen rises in prescription rates of such medicines, which can be a gateway to dangerous derivatives according to experts.

Read More »

GlaxoSmithKline’s new boss struggles to sell cure for drugmaker

GlaxoSmithKline’s new chief executive is facing a battle to convince investors she has the right prescription for growth at Britain’s biggest drugmaker. Emma Walmsley wants to boost the core pharmaceuticals division and also bulk up GSK’s big consumer healthcare operation, a twin-track strategy that could strain finances and has fueled fears for the dividend.

Read More »

Americans want to see a bipartisan fix for Obamacare: Reuters/Ipsos poll

As Republican and Democratic lawmakers clash over the future of Obamacare, Americans largely are eager for a bipartisan solution to its shortcomings, according to a Reuters/Ipsos opinion poll.

Read More »

Neos Therapeutics Jumps After PDL BioPharma Makes an All-Cash Take Out Offer

Shares of Neos Therapeutics soared more than 38 percent after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287 million.

Read More »

High cholesterol levels among U.S. adults declining: CDC report

The prevalence of U.S. adults with high cholesterol declined significantly between 1999-2000 and 2015-2016, achieving a long-term public health goal, according to data released by the Centers for Disease Control and Prevention’s National Center for Health Statistics.

Read More »

Medical Advertising Hall of Fame names Robert Leverte 2018 Inductee

The membership of the Medical Advertising Hall of Fame elected Robert Leverte as its 2018 inductee. Leverte’s career included founding ERS – an in-house ad agency at ER Squibb – co-founding Ruvane-Leverte advertising, Chairman at Bozell Jacobs Medical Group and CEO of the Leverte Companies.

Read More »

Ablynx Banks $200M IPO in Nasdaq Debut

Ghent, Belgium-based Ablynx NV announced the price of its U.S. initial public offering (IPO) at $17.50.

Read More »

MacroGenics, Incyte Score $900M R&D Deal

Icyte Corporation struck a deal worth up to $900 million with Maryland-based MacroGenics Inc. for that company’s investigational PD-1 inhibitor.

Read More »

U.S. committee recommends GSK shingles vaccine over Merck rival

The committee responsible for U.S. vaccination schedules gave a preferential recommendation to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck’s established product Zostavax.

Read More »

GSK ready to build drug testing in EU as Brexit looms

Britain’s biggest drugmaker GlaxoSmithKline is moving ahead with Brexit contingency planning “right now,” including preparing a system to test drugs in the European Union if Britain crashes out of the bloc without a trade deal.

Read More »

U.S. lawmakers will not tackle healthcare this year, Ryan says: Reuters interview

Republican lawmakers will not take up a bipartisan plan to stabilize Obamacare insurance markets or try again to repeal and replace the law during 2017 House of Representatives Speaker Paul Ryan said, signaling his party was shelving the matter until the 2018 U.S. congressional election year.

Read More »

Baxter expects $70 million hit to fourth-quarter 2017 sales from Hurricane Maria

U.S. hospital products maker Baxter International Inc. forecast a nearly $70 million hit to its fourth-quarter 2017 revenue, due to manufacturing disruptions arising from Hurricane Maria.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom